John A Messenheimer Selected Research

Lamotrigine (Lamictal)

8/2014	Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy.
5/2013	Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.
1/2012	Lamotrigine XR conversion to monotherapy: first study using a historical control group.
3/2009	Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy.
8/2008	Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old.
3/2008	Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
1/2008	Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs.
10/2007	Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy.
8/2006	Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
6/2005	Lamotrigine therapy in patients requiring a change in antiepileptic drug regimen.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John A Messenheimer Research Topics

Disease

10	Seizures (Absence Seizure) 01/2022 - 08/2004
9	Epilepsy (Aura) 12/2015 - 08/2004
3	Partial Epilepsies (Epilepsy, Partial) 01/2022 - 03/2009
3	Juvenile Myoclonic Epilepsy 08/2006 - 08/2004
1	Drug Resistant Epilepsy 01/2022
1	Epileptic Syndromes 12/2015
1	Poisoning 05/2013
1	Heart Failure 05/2013
1	Headache (Headaches) 05/2013
1	Exanthema (Rash) 05/2013
1	Dizziness (Lightheadedness) 05/2013
1	Fatigue 03/2009
1	Confusion (Bewilderment) 03/2009
1	Myoclonus (Nocturnal Myoclonus) 08/2006
1	Lennox Gastaut Syndrome 08/2006
1	Apnea 08/2006
1	Complex Partial Epilepsy (Psychomotor Epilepsy) 01/2005

Drug/Important Bio-Agent (IBA)

14	Lamotrigine (Lamictal)FDA LinkGeneric 08/2014 - 08/2004
6	Anticonvulsants (Antiepileptic Drugs)IBA 01/2012 - 08/2004
6	Valproic Acid (Depakote)FDA LinkGeneric 01/2012 - 08/2004
2	Pharmaceutical PreparationsIBA 01/2022 - 12/2015
2	Levetiracetam (Keppra)FDA LinkGeneric 03/2009 - 01/2008
1	CannabidiolIBA 01/2022
1	TabletsIBA 01/2012
1	Delayed-Action PreparationsIBA 03/2008
1	Biological ProductsIBA 01/2008
1	Antidepressive Agents (Antidepressants)IBA 01/2008
1	Oxcarbazepine (Trileptal)FDA LinkGeneric 01/2008
1	Phenobarbital (Luminal)FDA Link 01/2008
1	Tiagabine (Gabitril)FDA Link 01/2008
1	Topiramate (Topamax)FDA LinkGeneric 01/2008
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2008
1	GABA AgentsIBA 01/2008
1	Vigabatrin FDA Link 01/2008
1	gamma-Aminobutyric Acid (GABA)IBA 01/2005
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2005
1	Carbamazepine (Tegretol)FDA LinkGeneric 08/2004

Therapy/Procedure

8	Therapeutics 12/2015 - 01/2005
1	Drug Therapy (Chemotherapy) 05/2005